Survival and follow-up by race and ethnicity of 16 115 patients included in this report
| Race and ethnicity . | No. eligible . | 5-year EFS ± SE . | No. of relapses∗ (% per protocol) . | Time to relapse† in months, median (range) . | Median follow-up in months from diagnosis‡ . | Median follow-up in months from relapse§ . |
|---|---|---|---|---|---|---|
| Hispanic of all races | 3190 | 79.9% ± 0.7% | 492 (15.4%) | 29.8 (0.9-176.0) | 122.2 | 72.7 |
| NH White | 9584 | 85.3% ± 0.4% | 1147 (12.0%) | 33.4 (0.3-186.0) | 122.2 | 69.8 |
| NH Black | 1014 | 80.3% ± 1.3% | 145 (14.3%) | 25.3 (0.7-108.1) | 116.4 | 70.1 |
| NH Asian | 639 | 83.7% ± 1.5% | 65 (10.2%) | 30.4 (1.2-111.5) | 117.2 | 63.5 |
| NH Other | 176 | 81.4% ± 3.0% | 20 (11.4%) | 20.5 (3.4-84.0) | 121.1 | 59.0 |
| Other/Unknown | 1512 | 82.6% ± 1.0% | 184 (12.2%) | 26.9 (0.3-139.5) | 122.2 | 74.0 |
| Total | 16 115 | 83.5% ± 0.3% | 2053 (12.7%) | 31.0 (0.3-186.0) | 121.7 | 70.5 |
| Race and ethnicity . | No. eligible . | 5-year EFS ± SE . | No. of relapses∗ (% per protocol) . | Time to relapse† in months, median (range) . | Median follow-up in months from diagnosis‡ . | Median follow-up in months from relapse§ . |
|---|---|---|---|---|---|---|
| Hispanic of all races | 3190 | 79.9% ± 0.7% | 492 (15.4%) | 29.8 (0.9-176.0) | 122.2 | 72.7 |
| NH White | 9584 | 85.3% ± 0.4% | 1147 (12.0%) | 33.4 (0.3-186.0) | 122.2 | 69.8 |
| NH Black | 1014 | 80.3% ± 1.3% | 145 (14.3%) | 25.3 (0.7-108.1) | 116.4 | 70.1 |
| NH Asian | 639 | 83.7% ± 1.5% | 65 (10.2%) | 30.4 (1.2-111.5) | 117.2 | 63.5 |
| NH Other | 176 | 81.4% ± 3.0% | 20 (11.4%) | 20.5 (3.4-84.0) | 121.1 | 59.0 |
| Other/Unknown | 1512 | 82.6% ± 1.0% | 184 (12.2%) | 26.9 (0.3-139.5) | 122.2 | 74.0 |
| Total | 16 115 | 83.5% ± 0.3% | 2053 (12.7%) | 31.0 (0.3-186.0) | 121.7 | 70.5 |
EFS, event-free survival (from time of original diagnosis); SE, standard error.
Percentage of total eligible patients (patients who enrolled in any included protocol who experienced relapse as first event) in this row provided in the second column of the table.
Time in months from initial diagnosis to relapse among relapsed patients.
Median follow-up time in months from initial diagnosis among relapsed patients who were alive as of the last follow-up date.
Median follow-up time in months from relapse diagnosis among relapsed patients who were alive as of the last follow-up date.